MARKET

ACXP

ACXP

Acurx Pharmaceuticals Inc
NASDAQ
2.090
-0.030
-1.42%
After Hours: 2.080 -0.01 -0.48% 19:24 05/08 EDT
OPEN
2.120
PREV CLOSE
2.120
HIGH
2.120
LOW
2.030
VOLUME
60.40K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
1.326
MARKET CAP
8.94M
P/E (TTM)
-0.3932
1D
5D
1M
3M
1Y
5Y
1D
Acurx files to sell 1.65M shares of common stock for holders
TipRanks · 6d ago
Acurx files to sell 1.3M shares of common stock for holders
TipRanks · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Krystal Biotech (KRYS), Incyte (INCY)
TipRanks · 6d ago
Acurx DNA pol IIIC inhibitors spare gut microbiome in MRSA mouse study, poster shows
PUBT · 6d ago
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
PR Newswire · 6d ago
Weekly Report: what happened at ACXP last week (0427-0501)?
Weekly Report · 05/04 10:28
Acurx CEO to join Alliance Global Partners Healthcare Company Showcase fireside chat
PUBT · 04/29 12:00
Weekly Report: what happened at ACXP last week (0420-0424)?
Weekly Report · 04/27 10:31
More
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Webull offers Acurx Pharmaceuticals Inc stock information, including NASDAQ: ACXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACXP stock methods without spending real money on the virtual paper trading platform.